The Blood-based Biomarkers Market was valued at USD 7.85 billion in 2024, and is projected to reach USD 11.58 billion by 2030, rising at a CAGR of 7.20%. The market is expected to expand at a CAGR of 7.2% from 2025 to 2030. Rise in the prevalence of chronic diseases along with expanding research and funding drives the blood based biomarkers industry. As the demand for non-invasive diagnostic tools increases, governments, private sectors, and research institutions are prioritizing the funding of studies focused on developing and validating blood-based biomarkers for a wide range of diseases, including cancer, cardiovascular disorders, and neurological conditions. This increased investment enables innovative breakthroughs, enhances the accuracy and reliability of biomarkers, and accelerates the commercialization of new diagnostic tests. Additionally, the growing collaboration between academic institutions, biotechnology companies, and healthcare providers fosters the development of novel technologies, further driving market expansion and improving patient care outcomes.
Technological advancements and launches significantly drives the market, as innovations in high-throughput screening, next-generation sequencing (NGS), and mass spectrometry enhance the sensitivity and precision of biomarker detection. These advancements enable the identification of previously undetectable biomarkers, expanding the range of diseases that can be diagnosed through blood tests. Additionally, the development of microfluidic devices and wearable sensors allows for faster, more cost-effective, and less invasive testing. As technology continues to improve, it enhances the scalability and clinical applicability of blood-based biomarker assays, making them more accessible and valuable for early disease detection, personalized medicine, and monitoring treatment efficacy, thus fueling market growth.
The announcement of Exact Sciences Corp.'s promising performance data for its blood-based colorectal cancer screening test highlights a major advancement for the blood-based biomarker sector: the increasing effectiveness of early detection tests. With sensitivity rates of 88.3% for CRC and 31.2% for advanced precancerous lesions, coupled with a high specificity of 90.1%, the success of such tests reinforces the growing potential of blood-based diagnostics in cancer screening. As more innovative blood-based tests demonstrate high accuracy and reliability, the demand for these non-invasive, early detection solutions is expected to surge, driving further advancements in the market. This progress encourages investment, enhances patient outcomes, and strengthens the adoption of blood-based biomarkers across multiple cancer types.
This product will be delivered within 1-3 business days.
Technological advancements and launches significantly drives the market, as innovations in high-throughput screening, next-generation sequencing (NGS), and mass spectrometry enhance the sensitivity and precision of biomarker detection. These advancements enable the identification of previously undetectable biomarkers, expanding the range of diseases that can be diagnosed through blood tests. Additionally, the development of microfluidic devices and wearable sensors allows for faster, more cost-effective, and less invasive testing. As technology continues to improve, it enhances the scalability and clinical applicability of blood-based biomarker assays, making them more accessible and valuable for early disease detection, personalized medicine, and monitoring treatment efficacy, thus fueling market growth.
The announcement of Exact Sciences Corp.'s promising performance data for its blood-based colorectal cancer screening test highlights a major advancement for the blood-based biomarker sector: the increasing effectiveness of early detection tests. With sensitivity rates of 88.3% for CRC and 31.2% for advanced precancerous lesions, coupled with a high specificity of 90.1%, the success of such tests reinforces the growing potential of blood-based diagnostics in cancer screening. As more innovative blood-based tests demonstrate high accuracy and reliability, the demand for these non-invasive, early detection solutions is expected to surge, driving further advancements in the market. This progress encourages investment, enhances patient outcomes, and strengthens the adoption of blood-based biomarkers across multiple cancer types.
Blood Based Biomarkers Market Report Highlights
- In 2024, the genetic biomarkers segment was the largest revenue-generating sector of the blood based biomarkers industry. This is attributed to the growing adoption of genetic biomarkers in blood-based diagnostics is driven by advancements in comprehensive genomic profiling.
- Cancer was the most dominating segment in 2024 due to the consistent research, extensive collaborations among industry leaders to develop blood-based biomarkers for early diagnosis. Increasing cases of cancer and thereby rise in the demand for non invasive methods for diagnosis fuel the segment’s growth.
- Next-Generation Sequencing (NGS) segment dominated the market in 2024 due to the advancements in the technology and rising focus of several key players to develop innovative blood-based biomarkers.
- Hospitals and Clinics segment held the largest share of the end use segment in 2024. This dominance is attributed to the rising prevalence of chronic diseases. As hospitals are center to all the advanced diagnostic services, such as blood-based biomarker testing, patients entrust the established hospitals thus, fueling market growth.
- The North American region is set to reign the global market in the year 2024. The rising implementation of advanced diagnostic tools, increasing wareness, presence of industry leaders in the region and regulatory approvals are anticipated to contribute to the market growth
This report addresses:
- Market intelligence to enable effective decision-making.
- Market estimates and forecasts from 2018 to 2030.
- Growth opportunities and trend analyses.
- Segment and regional revenue forecasts for market assessment.
- Competition strategy and market share analysis.
- Product innovation listings for you to stay ahead of the curve.
- COVID-19's impact and how to sustain in this fast-evolving market.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Blood Based Biomarkers Market Variables, Trends & Scope
Chapter 4. Blood Based Biomarkers Market: Type Estimates & Trend Analysis
Chapter 5. Blood Based Biomarkers Market: Application Estimates & Trend Analysis
Chapter 6. Blood Based Biomarkers Market: End Use Estimates & Trend Analysis
Chapter 7. Blood Based Biomarkers Market: Regional Estimates & Trend Analysis by Type, Application, Technology, and End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Blood-based Biomarkers market report include:- Abbott
- BIOMÉRIEUX
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc
- Cleveland Diagnostics, Inc.
- Sysmex Corporation
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 7.85 Billion |
| Forecasted Market Value ( USD | $ 11.58 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
